Search alternatives:
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
641
-
642
-
643
-
644
SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP.
Published 2025Subjects: -
645
-
646
AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner.
Published 2025“…Cell numbers were significantly decreased in cells after treatment with AZ10606120 (50µM) compared to both temozolomide (TMZ; 50µM) treatment and untreated controls. …”
-
647
-
648
-
649
-
650
-
651
-
652
-
653
Flowchart of the screening process.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
654
Result of the AMSTAR-2 assessments.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
655
Characteristics of included reviews.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
656
Result of the PRISMA assessments.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
657
Result of the ROBIS assessments.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
658
Cohort characteristics.
Published 2025“…</p><p>Results</p><p>Upon initiation of CPB we observed a significant decrease in arterial whole blood redox potential (101.90 mV + /- 11.52 vs. 41.80 mV + /- 10,26; p < 0.0001). …”
-
659
Study selection criteria.
Published 2025“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”
-
660
PICOS criteria for the SLR.
Published 2025“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”